| David Crockford, RegeneRx’s vice president for clinical and regulatory affairs presented an overview of the biological properties that support Tâ4’s near term and long term clinical applications. Mr. Crockford noted that special emphasis is being placed on the development of RGN-352 for the systemic treatment of patients with ST-elevation myocardial infarction in combination with percutaneous coronary intervention, the current standard of care in most western countries for this common type of heart attack. The goal with RGN-352 is to prevent or repair continued damage to cardiac tissue post-heart attack, when such tissue around the damaged site remains at risk. :theflyonthewall.com |
Subscribe for More Information